{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:09:43Z","timestamp":1789013383175,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11523-026-01198-0","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:11:25Z","timestamp":1770181885000},"page":"147-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-633X","authenticated-orcid":false,"given":"Marianna Rita","family":"Brogna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Varone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Montone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Schiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"DelSesto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nubia","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Prota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Barra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Collina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"4","key":"1198_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cpet.2023.04.002","volume":"18","author":"M Roy","year":"2023","unstructured":"Roy M, Fowler AM, Ulaner GA, Mahajan A. Molecular classification of breast cancer. PET Clin. 2023;18(4):441\u201358. https:\/\/doi.org\/10.1016\/j.cpet.2023.04.002.","journal-title":"PET Clin"},{"issue":"1","key":"1198_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5858\/arpa.2022-0070-RA","volume":"147","author":"X Zhang","year":"2023","unstructured":"Zhang X. Molecular classification of breast cancer: relevance and challenges. Arch Pathol Lab Med. 2023;147(1):46\u201351. https:\/\/doi.org\/10.5858\/arpa.2022-0070-RA.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"1198_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph14010068","volume":"14","author":"LY Yu","year":"2017","unstructured":"Yu LY, Tang J, Zhang CM, Zeng WJ, Yan H, Li MP, et al. New immunotherapy strategies in breast cancer. Int J Environ Res Public Health. 2017;14(1):68. https:\/\/doi.org\/10.3390\/ijerph14010068.","journal-title":"Int J Environ Res Public Health"},{"key":"1198_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01804","volume":"8","author":"I Corraliza-Gorj\u00f3n","year":"2017","unstructured":"Corraliza-Gorj\u00f3n I, Somovilla-Crespo B, Santamaria S, Garcia-Sanz JA, Kremer L. New strategies using antibody combinations to increase cancer treatment effectiveness. Front Immunol. 2017;8:1804. https:\/\/doi.org\/10.3389\/fimmu.2017.01804.","journal-title":"Front Immunol"},{"issue":"5","key":"1198_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052433","volume":"22","author":"V Sivaganesh","year":"2021","unstructured":"Sivaganesh V, Promi N, Maher S, Peethambaran B. Emerging immunotherapies against novel molecular targets in breast cancer. Int J Mol Sci. 2021;22(5):2433. https:\/\/doi.org\/10.3390\/ijms22052433.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"1198_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147517","volume":"25","author":"K Dvir","year":"2024","unstructured":"Dvir K, Giordano S, Leone JP. Immunotherapy in breast cancer. Int J Mol Sci. 2024;25(14):7517. https:\/\/doi.org\/10.3390\/ijms25147517.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1198_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, Lipatov O, Im SA, Goncalves A, Mu\u00f1oz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(4):499\u2013511. https:\/\/doi.org\/10.1016\/S1470-2045(20)30754-3.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1198_CR8","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens LA, Adams S, Barrios CH, Di\u00e9ras V, Iwata H, Loi S, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32(8):983\u201393. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.355.","journal-title":"Ann Oncol"},{"issue":"10","key":"1198_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00674-6","volume":"19","author":"D Romero","year":"2022","unstructured":"Romero D. KEYNOTE-355 - os benefit now reported. Nat Rev Clin Oncol. 2022;19(10):616. https:\/\/doi.org\/10.1038\/s41571-022-00674-6.","journal-title":"Nat Rev Clin Oncol"},{"key":"1198_CR10","doi-asserted-by":"publisher","DOI":"10.21037\/tbcr-23-33","volume":"5","author":"H Zhang","year":"2023","unstructured":"Zhang H, Jin X, Bian L. Torchlight trial, brightening the life of more patients with advanced triple-negative breast cancer. Transl Breast Cancer Res. 2023;5:1. https:\/\/doi.org\/10.21037\/tbcr-23-33.","journal-title":"Transl Breast Cancer Res"},{"issue":"9","key":"1198_CR11","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1038\/s41591-024-03088-2","volume":"30","author":"H Mo","year":"2024","unstructured":"Mo H, Yu Y, Sun X, Ge H, Yu L, Guan X, et al. Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nat Med. 2024;30(9):2528\u201339. https:\/\/doi.org\/10.1038\/s41591-024-03088-2.","journal-title":"Nat Med"},{"key":"1198_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1097983","volume":"13","author":"T Yang","year":"2023","unstructured":"Yang T, Kang L, Li D, Song Y. Immunotherapy for HER-2 positive breast cancer. Front Oncol. 2023;13:1097983. https:\/\/doi.org\/10.3389\/fonc.2023.1097983.","journal-title":"Front Oncol"},{"issue":"1","key":"1198_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00704-9","volume":"10","author":"F Cardoso","year":"2024","unstructured":"Cardoso F, Hirshfield KM, Kraynyak KA, Tryfonidis K, Bardia A. Immunotherapy for hormone receptor\u2012positive HER2-negative breast cancer. NPJ Breast Cancer. 2024;10(1):104. https:\/\/doi.org\/10.1038\/s41523-024-00704-9.","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"1198_CR14","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.21037\/tcr-23-726","volume":"12","author":"J Phillipps","year":"2023","unstructured":"Phillipps J, Zhou AY, Butt OH, Ansstas G. PARP inhibition and immunotherapy: a promising duo in fighting cancer. Transl Cancer Res. 2023;12(9):2433\u20137. https:\/\/doi.org\/10.21037\/tcr-23-726.","journal-title":"Transl Cancer Res"},{"issue":"11","key":"1198_CR15","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1080\/21645515.2020.1738167","volume":"16","author":"A Gupta","year":"2020","unstructured":"Gupta A, Kumar Y. Bispecific antibodies: a novel approach for targeting prominent biomarkers. Hum Vaccin Immunother. 2020;16(11):2831\u20139. https:\/\/doi.org\/10.1080\/21645515.2020.1738167.","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"1198_CR16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1609783.","journal-title":"N Engl J Med"},{"issue":"8","key":"1198_CR17","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1080\/19420862.2018.1519631","volume":"10","author":"HA Cooke","year":"2018","unstructured":"Cooke HA, Arndt J, Quan C, Shapiro RI, Wen D, Foley S, et al. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies. MAbs. 2018;10(8):1248\u201359. https:\/\/doi.org\/10.1080\/19420862.2018.1519631.","journal-title":"MAbs"},{"issue":"1","key":"1198_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00508-3","volume":"9","author":"V Debien","year":"2023","unstructured":"Debien V, De Caluw\u00e9 A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9(1):7. https:\/\/doi.org\/10.1038\/s41523-023-00508-3.","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"1198_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"ME Goebeler","year":"2020","unstructured":"Goebeler ME, Bargou RC. T cell-engaging therapies\u2014BiTEs and beyond. Nat Rev Clin Oncol. 2020;17(7):418\u201334. https:\/\/doi.org\/10.1038\/s41571-020-0347-5.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1198_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11899-023-00714-7","volume":"19","author":"J Lantz","year":"2024","unstructured":"Lantz J, Pham N, Jones C, Reed D, El Chaer F, Keng M. Blinatumomab in practice. Curr Hematol Malig Rep. 2024;19(1):1\u20138. https:\/\/doi.org\/10.1007\/s11899-023-00714-7.","journal-title":"Curr Hematol Malig Rep"},{"key":"1198_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1492782","volume":"15","author":"MA Nix","year":"2024","unstructured":"Nix MA, Lareau CA, Verboon J, Kugler DG. Identifying optimal tumor-associated antigen combinations with single-cell genomics to enable multi-targeting therapies. Front Immunol. 2024;15:1492782. https:\/\/doi.org\/10.3389\/fimmu.2024.1492782.","journal-title":"Front Immunol"},{"key":"1198_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.18433\/jpps31864","volume":"24","author":"M Eini","year":"2021","unstructured":"Eini M, Zainodini N, Montazeri H, Mirzabeigi P, Tarighi P. A review of therapeutic antibodies in breast cancer. J Pharm Pharm Sci. 2021;24:363\u201380. https:\/\/doi.org\/10.18433\/jpps31864.","journal-title":"J Pharm Pharm Sci"},{"issue":"12","key":"1198_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005543","volume":"10","author":"M Yi","year":"2022","unstructured":"Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y, et al. Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer. 2022;10(12):e005543. https:\/\/doi.org\/10.1136\/jitc-2022-005543.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"1198_CR24","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1517\/13543784.17.10.1553","volume":"17","author":"P Kiewe","year":"2008","unstructured":"Kiewe P, Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008;17(10):1553\u20138. https:\/\/doi.org\/10.1517\/13543784.17.10.1553.","journal-title":"Expert Opin Investig Drugs"},{"key":"1198_CR25","doi-asserted-by":"publisher","unstructured":"Tebotelimab is safe and effective across multiple cancer types. Cancer Discov. 2024;14(1):OF4. https:\/\/doi.org\/10.1158\/2159-8290.CD-RW2023-174.","DOI":"10.1158\/2159-8290.CD-RW2023-174"},{"issue":"5","key":"1198_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","volume":"35","author":"L Pusztai","year":"2024","unstructured":"Pusztai L, Denkert C, O\u2019Shaughnessy J, Cortes J, Dent R, McArthur H, et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol. 2024;35(5):429\u201336. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.002.","journal-title":"Ann Oncol"},{"issue":"2","key":"1198_CR27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1158\/1078-0432.CCR-05-2005","volume":"12","author":"RC Grabert","year":"2006","unstructured":"Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, et al. Human T cells armed with Her2\/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res. 2006;12(2):569\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2005.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1198_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-00219","volume":"9","author":"LG Lum","year":"2021","unstructured":"Lum LG, Al-Kadhimi Z, Deol A, et al. Phase II clinical trial using anti-CD3 \u00d7 anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0\u20132+) metastatic breast cancer. J Immunother Cancer. 2021;9(6):e002194. https:\/\/doi.org\/10.1136\/jitc-2020-00219.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1198_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1089\/scd.1.1995.4.471","volume":"4","author":"FH Valone","year":"1995","unstructured":"Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Ernstoff MS, et al. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2\/neu. J Hematother. 1995;4(5):471\u20135. https:\/\/doi.org\/10.1089\/scd.1.1995.4.471.","journal-title":"J Hematother"},{"key":"1198_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1385\/1-59259-071-3:793","volume":"39","author":"PA Kaufman","year":"2001","unstructured":"Kaufman PA, Wallace PK, Valone FH, Wells WA, Memoli VA, Ernstoff MS. Bispecific antibody MDX-210 for treatment of advanced ovarian and breast cancer. Methods Mol Med. 2001;39:793\u2013806. https:\/\/doi.org\/10.1385\/1-59259-071-3:793.","journal-title":"Methods Mol Med"},{"issue":"4","key":"1198_CR31","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1158\/1078-0432.CCR-21-2827","volume":"28","author":"J Zhang","year":"2022","unstructured":"Zhang J, Ji D, Cai L, Yao H, Yan M, Wang X, et al. First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: results from a phase I study. Clin Cancer Res. 2022;28(4):618\u201328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2827.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1198_CR32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cac2.12662","volume":"45","author":"J Ma","year":"2025","unstructured":"Ma J, Wang J, Xu T, Ouyang Q, Wang X, Wang J, et al. Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial. Cancer Commun (Lond). 2025;45(4):476\u201385. https:\/\/doi.org\/10.1002\/cac2.12662.","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"1198_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.37349\/etat.2021.00037","volume":"2","author":"P Tarantino","year":"2021","unstructured":"Tarantino P, Morganti S, Curigliano G. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Explor Target Antitumor Ther. 2021;2(2):139\u201355. https:\/\/doi.org\/10.37349\/etat.2021.00037.","journal-title":"Explor Target Antitumor Ther"},{"issue":"1","key":"1198_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100790","volume":"8","author":"J Uliano","year":"2023","unstructured":"Uliano J, Corvaja C, Curigliano G, Tarantino P. Targeting HER3 for cancer treatment: a new horizon for an old target. ESMO Open. 2023;8(1):100790. https:\/\/doi.org\/10.1016\/j.esmoop.2023.100790.","journal-title":"ESMO Open"},{"issue":"10","key":"1198_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003468","volume":"9","author":"H Liu","year":"2021","unstructured":"Liu H, Bai L, Huang L, Ning N, Li L, Li Y, et al. Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer. J Immunother Cancer. 2021;9(10):e003468. https:\/\/doi.org\/10.1136\/jitc-2021-003468.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"1198_CR36","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1007\/s10147-024-02589-x","volume":"29","author":"Y Naito","year":"2024","unstructured":"Naito Y, Nakamura S, Kawaguchi-Sakita N, Ishida T, Nakayama T, Yamamoto Y, et al. Preliminary results from ASCENT-J02: a phase 1\/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors. Int J Clin Oncol. 2024;29(11):1684\u201395. https:\/\/doi.org\/10.1007\/s10147-024-02589-x.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"1198_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01649-z","volume":"17","author":"NK Heater","year":"2024","unstructured":"Heater NK, Warrior S, Lu J. Current and future immunotherapy for breast cancer. J Hematol Oncol. 2024;17(1):131. https:\/\/doi.org\/10.1186\/s13045-024-01649-z.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1198_CR38","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2217\/fon-2023-0188","volume":"20","author":"A Bardia","year":"2024","unstructured":"Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, et al. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+\/HER2- breast cancer. Future Oncol. 2024;20(8):423\u201336. https:\/\/doi.org\/10.2217\/fon-2023-0188.","journal-title":"Future Oncol"},{"key":"1198_CR39","doi-asserted-by":"publisher","first-page":"175883592513279","DOI":"10.1177\/17588359251327992","volume":"17","author":"P Schmid","year":"2025","unstructured":"Schmid P, Oliveira M, O\u2019Shaughnessy J, Cristofanilli M, Graff SL, Im SA, et al. TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol. 2025;17:17588359251327992. https:\/\/doi.org\/10.1177\/17588359251327992.","journal-title":"Ther Adv Med Oncol."},{"issue":"10","key":"1198_CR40","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76(10):3003\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1313.","journal-title":"Cancer Res"},{"issue":"6","key":"1198_CR41","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41571-025-01022-0","volume":"22","author":"D Killock","year":"2025","unstructured":"Killock D. Sacituzumab tirumotecan improves OS in mTNBC. Nat Rev Clin Oncol. 2025;22(6):382. https:\/\/doi.org\/10.1038\/s41571-025-01022-0.","journal-title":"Nat Rev Clin Oncol"},{"key":"1198_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.919072","volume":"12","author":"C Luo","year":"2022","unstructured":"Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and prospect of immunotherapy for triple-negative breast cancer. Front Oncol. 2022;12:919072. https:\/\/doi.org\/10.3389\/fonc.2022.919072.","journal-title":"Front Oncol"},{"issue":"2","key":"1198_CR43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1158\/1078-0432.CCR-21-2182","volume":"28","author":"S Adams","year":"2022","unstructured":"Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, et al. A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART, SWOG S1609). Clin Cancer Res. 2022;28(2):271\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2182.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1198_CR44","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1158\/2159-8290.CD-23-0762","volume":"14","author":"L Monteran","year":"2024","unstructured":"Monteran L, Ershaid N, Scharff Y, Zoabi Y, Sanalla T, Ding Y, et al. Combining TIGIT blockade with MDSC inhibition hinders breast cancer bone metastasis by activating antitumor immunity. Cancer Discov. 2024;14(7):1252\u201375. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0762.","journal-title":"Cancer Discov"},{"issue":"1","key":"1198_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, et al. Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol. 2023;16(1):100. https:\/\/doi.org\/10.1186\/s13045-023-01497-3.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1198_CR46","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","volume":"25","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, et al. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res. 2019;25(7):2033\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2275.","journal-title":"Clin Cancer Res"},{"key":"1198_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/BCTT.S448191","volume":"16","author":"MR Monteiro","year":"2024","unstructured":"Monteiro MR, Nunes NCC, Junior AADS, F\u00eade ABS, Bretas GO, Souza CP, et al. Antibody-drug conjugates in breast cancer: a comprehensive review of how to selectively deliver payloads. Breast Cancer (Dove Med Press). 2024;16:51\u201370. https:\/\/doi.org\/10.2147\/BCTT.S448191.","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"1198_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107695","volume":"151","author":"M Bhagyalalitha","year":"2024","unstructured":"Bhagyalalitha M, Handattu Shankaranarayana A, Arun Kumar S, Singh M, Pujar KG, Bidye D, et al. Advances in HER2-targeted therapies: from monoclonal antibodies to dual inhibitors developments in cancer treatment. Bioorg Chem. 2024;151:107695. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107695.","journal-title":"Bioorg Chem"},{"issue":"6","key":"1198_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101575","volume":"5","author":"E Agostinetto","year":"2024","unstructured":"Agostinetto E, Curigliano G, Piccart M. Emerging treatments in HER2-positive advanced breast cancer: keep raising the bar. Cell Rep Med. 2024;5(6):101575. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101575.","journal-title":"Cell Rep Med"},{"issue":"4","key":"1198_CR50","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s12254-018-0441-x","volume":"11","author":"R Bartsch","year":"2018","unstructured":"Bartsch R, Bergen E. ASCO 2018: highlights in HER2-positive metastatic breast cancer. Memo. 2018;11(4):280\u20133. https:\/\/doi.org\/10.1007\/s12254-018-0441-x.","journal-title":"Memo"},{"key":"1198_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101068","volume":"74","author":"B Zhang","year":"2024","unstructured":"Zhang B, Shi J, Shi X, Xu X, Gao L, Li S, et al. Development and evaluation of a human CD47\/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy. Drug Resist Updat. 2024;74:101068. https:\/\/doi.org\/10.1016\/j.drup.2024.101068.","journal-title":"Drug Resist Updat"},{"issue":"19","key":"1198_CR52","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-18-3654","volume":"25","author":"MJ Hinner","year":"2019","unstructured":"Hinner MJ, Aiba RSB, Jaquin TJ, Berger S, D\u00fcrr MC, Schlosser C, et al. Tumor-localized costimulatory T-cell engagement by the 4-1BB\/HER2 bispecific antibody-anticalin fusion PRS-343. Clin Cancer Res. 2019;25(19):5878\u201389. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3654.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1198_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021487","volume":"6","author":"H Xie","year":"2011","unstructured":"Xie H, Lin L, Tong L, Jiang Y, Zheng M, Chen Z, et al. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS ONE. 2011;6(7):e21487. https:\/\/doi.org\/10.1371\/journal.pone.0021487.","journal-title":"PLoS ONE"},{"issue":"6","key":"1198_CR54","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5579","volume":"63","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li L, Chu C, Wei X, Liu Q, Wang R, et al. CUDC-101 is a potential target inhibitor for the EGFR-overexpression bladder cancer cells. Int J Oncol. 2023;63(6):131. https:\/\/doi.org\/10.3892\/ijo.2023.5579.","journal-title":"Int J Oncol"},{"issue":"1","key":"1198_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010124","volume":"16","author":"DF Chamorro","year":"2023","unstructured":"Chamorro DF, Somes LK, Hoyos V. Engineered adoptive T-cell therapies for breast cancer: current progress, challenges, and potential. Cancers (Basel). 2023;16(1):124. https:\/\/doi.org\/10.3390\/cancers16010124.","journal-title":"Cancers (Basel)"},{"key":"1198_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/srep20502","volume":"6","author":"D Huang","year":"2016","unstructured":"Huang D, Duan H, Huang H, Tong X, Han Y, Ru G, et al. Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. Sci Rep. 2016;6:20502. https:\/\/doi.org\/10.1038\/srep20502.","journal-title":"Sci Rep"},{"key":"1198_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1266450","volume":"14","author":"HR Lan","year":"2023","unstructured":"Lan HR, Chen M, Yao SY, Chen JX, Jin KT. Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview. Front Immunol. 2023;14:1266450. https:\/\/doi.org\/10.3389\/fimmu.2023.1266450.","journal-title":"Front Immunol"},{"issue":"7","key":"1198_CR58","doi-asserted-by":"publisher","first-page":"557","DOI":"10.7150\/jca.6689","volume":"4","author":"A Nakayama","year":"2013","unstructured":"Nakayama A, Takagi S, Yusa T, Yaguchi M, Hayashi A, Tamura T, et al. Antitumor activity of TAK-285, an investigational, non-Pgp substrate HER2\/EGFR kinase inhibitor, in cultured tumor cells, mouse and rat xenograft tumors, and in an HER2-positive brain metastasis model. J Cancer. 2013;4(7):557\u201365. https:\/\/doi.org\/10.7150\/jca.6689.","journal-title":"J Cancer"},{"issue":"15","key":"1198_CR59","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1200\/JCO.2005.05.3785","volume":"24","author":"J Baselga","year":"2006","unstructured":"Baselga J. Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question. J Clin Oncol. 2006;24(15):2225\u20136. https:\/\/doi.org\/10.1200\/JCO.2005.05.3785.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1198_CR60","first-page":"551","volume":"33","author":"W Jia","year":"2019","unstructured":"Jia W, Wang TZ. Effects of trastuzumab and lapatinib on HER2 positive breast cancer treatment. J Biol Regul Homeost Agents. 2019;33(2):551\u20135.","journal-title":"J Biol Regul Homeost Agents"},{"issue":"6","key":"1198_CR61","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"KA Won","year":"2020","unstructured":"Won KA, Spruck C. Triple-negative breast cancer therapy: current and future perspectives (review). Int J Oncol. 2020;57(6):1245\u201361. https:\/\/doi.org\/10.3892\/ijo.2020.5135.","journal-title":"Int J Oncol"},{"issue":"6","key":"1198_CR62","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/annonc\/mdz115","volume":"30","author":"A Marra","year":"2019","unstructured":"Marra A, Curigliano G. T-cell MHC class I bispecific antibodies to bypass loss in breast cancer. Ann Oncol. 2019;30(6):877\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdz115.","journal-title":"Ann Oncol"},{"issue":"10","key":"1198_CR63","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Sacituzumab govitecan: first approval. Drugs. 2020;80(10):1019\u201325. https:\/\/doi.org\/10.1007\/s40265-020-01337-5.","journal-title":"Drugs"},{"key":"1198_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190379","volume":"14","author":"D Shah","year":"2023","unstructured":"Shah D, Soper B, Shopland L. Cytokine release syndrome and cancer immunotherapies\u2014historical challenges and promising futures. Front Immunol. 2023;14:1190379. https:\/\/doi.org\/10.3389\/fimmu.2023.1190379.","journal-title":"Front Immunol"},{"issue":"1","key":"1198_CR65","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105. https:\/\/doi.org\/10.1186\/s12943-023-01805-y.","journal-title":"Mol Cancer"},{"issue":"4","key":"1198_CR66","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(4):e123\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.756.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"1198_CR67","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1007\/s10238-023-01177-z","volume":"23","author":"S Keshavarz","year":"2023","unstructured":"Keshavarz S, Wall JR, Keshavarz S, Vojoudi E, Jafari-Shakib R. Breast cancer immunotherapy: a comprehensive review. Clin Exp Med. 2023;23(8):4431\u201347. https:\/\/doi.org\/10.1007\/s10238-023-01177-z.","journal-title":"Clin Exp Med"},{"issue":"6","key":"1198_CR68","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood.2023023419","volume":"144","author":"J Kim","year":"2024","unstructured":"Kim J, Cho J, Lee MH, Yoon SE, Kim WS, Kim SJ. CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis. Blood. 2024;144(6):629\u201338. https:\/\/doi.org\/10.1182\/blood.2023023419.","journal-title":"Blood"},{"issue":"2","key":"1198_CR69","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cpt.3308","volume":"116","author":"K Lim","year":"2024","unstructured":"Lim K, Zhu XS, Zhou D, Ren S, Phipps A. Clinical pharmacology strategies for bispecific antibody development: learnings from FDA-approved bispecific antibodies in oncology. Clin Pharmacol Ther. 2024;116(2):315\u201327. https:\/\/doi.org\/10.1002\/cpt.3308.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01198-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01198-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01198-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:57:52Z","timestamp":1774630672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01198-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01198-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marianna Rita Brogna, Gerardo Ferrara, Valeria Varone, Angela Montone, Adriana Fava, Maria Rosaria Schiano, Michele DelSesto, Nubia Pizza, Annalisa Prota, Carmela Barra and Francesca Collina declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish"}},{"value":"All data generated or analyzed during this study are included in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Study concept and design:\n                      Marianna Rita Brogna and Francesca Collina.\n                      Data collection\n                      : Michele Del Sesto and Angela Montone and Adriana Fava.\n                      Drafting and revision of paper\n                      : Marianna Rita Brogna, Francesca Collina, Valeria Varone, Gerardo Ferrara. All authors have read, edited, and contributed to the content of this manuscript. This work has not been previously published and has not been considered for publication elsewhere.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}